EOLS
Evolus, Inc.- Healthcare
- Drug Manufacturers - Specialty & Generic
- $516M market cap
Forecast run · Sep 14, 2026Upside rank 372 of 3,136
Model Signal
ForecastQ Daily Probabilities
59.5%
46.9%
27.1%
Analyst Consensus
Recommendation2.15/5 Buy
Last price$7.84
Price target$18.40
Implied move+134.7%
Analysts13
ForecastQ Portfolios
EOLS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.